Conference item
A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Authors
- Publisher:
- Wiley
- Host title:
- Proceedings of the Lymphoma, Leukemia and Myeloma Congress (LLM Congress 2022)
- Journal:
- American Journal of Hematology More from this journal
- Volume:
- 97
- Article number:
- S5
- Publication date:
- 2022-10-13
- Acceptance date:
- 2022-09-19
- Event title:
- Lymphoma, Leukemia and Myeloma Congress (LLM Congress 2022)
- Event website:
- https://www.lymphomaandmyeloma.oncnet.com/
- Event start date:
- 2022-10-18
- Event end date:
- 2022-10-22
- DOI:
- EISSN:
-
1096-8652
- ISSN:
-
0361-8609
- Language:
-
English
- Keywords:
- Pubs id:
-
1288019
- Local pid:
-
pubs:1288019
- Deposit date:
-
2022-11-15
Terms of use
- Copyright holder:
- Wiley
- Copyright date:
- 2022
- Rights statement:
- © 2022 Wiley Periodicals LLC.
- Notes:
- This paper was presented at the Lymphoma, Leukemia and Myeloma Congress (LLM Congress 2022), 18th-22nd October 2022.
If you are the owner of this record, you can report an update to it here: Report update to this record